Overview

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Status:
NOT_YET_RECRUITING

Trial end date:
2027-06-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).

Phase:

PHASE1

Details

Lead Sponsor:

Celgene

Treatments:

Calcium Dobesilate
Dexamethasone